- Home
- RARE vs MLCO Comparison
RARE vs MLCO Comparison
Compare RARE & MLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | MLCO |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | 2013 | 2006 |
Fundamental Metrics
Financial Performance| Metric | RARE | MLCO |
|---|---|---|
| Price | $21.92 | $5.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 5 |
| Target Price | ★ $59.10 | $10.10 |
| AVG Volume (30 Days) | 1.4M | ★ 2.1M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $673,000,000.00 | N/A |
| Revenue This Year | $13.12 | $5.42 |
| Revenue Next Year | $37.80 | $4.37 |
| P/E Ratio | ★ N/A | $12.16 |
| Revenue Growth | ★ 20.13 | N/A |
| 52 Week Low | $18.29 | $5.19 |
| 52 Week High | $40.17 | $10.15 |
Technical Indicators
Market Signals| Indicator | RARE | MLCO |
|---|---|---|
| Relative Strength Index (RSI) | 39.50 | 54.49 |
| Support Level | $20.11 | $5.44 |
| Resistance Level | $23.44 | $6.07 |
| Average True Range (ATR) | 1.15 | 0.16 |
| MACD | -0.23 | 0.04 |
| Stochastic Oscillator | 11.98 | 59.77 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
About MLCO Melco Resorts & Entertainment Limited
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 84% from Macao, with the rest from overseas as of 2025.